Acquisitions, Investments, and Licenses - Acquisition Narrative (Details) $ / shares in Units, $ in Thousands				3 Months Ended		6 Months Ended
	Jun. 03, 2015 USD ($) $ / shares	May. 05, 2015 USD ($) $ / shares shares	Apr. 17, 2014 USD ($) shares	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)
Business Acquisition [Line Items]
In-process research and development				$ 0	$ 10,055	$ 0	$ 10,055
Common Stock
Business Acquisition [Line Items]
Stock price | $ / shares		$ 13.88
Bio-Reference
Business Acquisition [Line Items]
Consideration transferred	$ 1,300,000
Bio-Reference | Common Stock
Business Acquisition [Line Items]
Conversion ratio on stock	2.75
Stock price | $ / shares	$ 16.74
Acquired entity share price | $ / shares	$ 46.04
EirGen Pharma Ltd
Business Acquisition [Line Items]
Consideration transferred		$ 133,800
Cash paid at closing date		100,200
Common stock value		$ 33,600
Revenues						2,300
Net loss						(800)
EirGen Pharma Ltd | Common Stock
Business Acquisition [Line Items]
Delivery of common stock | shares		2,420,487
Inspiro
Business Acquisition [Line Items]
Cash paid at closing date			$ 1,500
Delivery of common stock | shares			999,556
Common stock value			$ 8,600
Inspiro stock purchase agreement percent			100.00%
In-process research and development			$ 10,100
Selling, General and Administrative Expenses | EirGen Pharma Ltd
Business Acquisition [Line Items]
Acquisition related costs						$ 500
Minimum | IPR&D assets | EirGen Pharma Ltd
Business Acquisition [Line Items]
Useful life		3 years
Maximum | IPR&D assets | EirGen Pharma Ltd
Business Acquisition [Line Items]
Useful life		20 years